刘文姬;刘志强;郭庆枝;孙莉;许振;

• 1:滨州医学院附属医院

摘要(Abstract)：

宫颈癌是第四大常见女性恶性肿瘤,是导致妇女癌症死亡的主要原因之一。宫颈癌筛查和预防宫颈HPV感染是防治宫颈癌的关键。HPV预防性疫苗的上市使宫颈癌成为目前唯一可早期预防并有望彻底根除的癌症。随着HPV疫苗接种作为宫颈癌预防策略的引入,HPV检测及细胞学检查在宫颈癌筛查中的价值随之发生变化,未来必将导致子宫颈癌筛查方案发生重大转变。现行的筛查策略正在受到挑战,新的筛查指南需进一步探索。

关键词(KeyWords)： 宫颈癌筛查;HPV病毒检测;细胞学检查;HPV疫苗

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 刘文姬;刘志强;郭庆枝;孙莉;许振;

DOI: 10.13283/j.cnki.xdfckjz.2018.03.017

参考文献(References)：

• [1]Saslow D,Solomon D,Lawson HW,et al.American cancer society,american society for colposcopy and cervical pathology,and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer[J].CA-Cancer J Clin,2012,62(3):147-172
• [2]Small W Jr,Bacon MA,Bajaj A,et al.Cervical Cancer:A Global Health Crisis[J].Cancer,2017,123(13):2404-2412
• [3]程琳,张琨,许天敏.预防性HPV疫苗的临床应用进展及思考[J].现代肿瘤医学,2017,25(2):328-331
• [4]Juckett G,Hartman-Adams H.Human papillomavirus:clinical manifestations and prevention[J].Am Fam Physic,2010,82(10):1209-1213
• [5]Zhai L,Tumban E.Gardasil-9:A global survey of projected efficacy[J].Antiviral Res,2016,130:101-109
• [6]Lee SJ,Yang A,Wu T,et al.Immonotherapy for human papillomavirus-associated disease and cervical cancer:review of clinical and translational research[J].J Gynecol Oncol,2016,27(5):e51
• [7]de Sanjose S,Quint WG,Alemany L,et al.Retrospective International Survey and HPV Time Trends Study Group.Human papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study[J].Lancet Oncol,2010,11(11):1048-1056
• [8]Munoz N,Bosch FX,de Sanjose S,et al.International agency for research on cancer multicenter cervical cancer study group.Epidemiologic classification of human papillomavirus types associated with cervical cancer[J].N Engl J Med,2003,348(6):518-527
• [9]Stokley S,Jeyarajah J,Yankey D,et al.Human papillomavirus vaccination coverage among adolescents,2007-2013,and postlicensure vaccine safety monitoring,2006-2014-United States[J].MMWR Morb Mortal Wkly Rep,2014,63(29):620-624
• [10]Crawford NW,Hodgson K,Gold M,et al.Adverse events following HPV immunization in australia:establishment of a clinical network[J].Hum Vaccin Immunother,2016,12(10):2662-2665
• [11]Glaxo Smith Kline Vaccine HPV-007 Study Group,Romanowski B,de Borba PC,et al.Sustained efficacy and immunegenicity of the human papillomavirus(HPV)-16/18 AS04-adjuvanted vaccine:analysis of a randomised placebo-controlled trial up to 6.4 years[J].Lancet,2009,374(9076):1975-1985
• [12]De Vincenzo R,Conte C,Ricci C,et al.Long-term efficacy and safety of human papillomavirus vaccination[J].lnt,J Womens Health,2014(6):999-1010
• [13]Garland SM,Hernandezavila M,Wheeler CM,et al.Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases[J].New Engl J Med,2007,356(19):1928-1943
• [14]Mariani L,Preti M,Cristoforoni P,et al.Overview of the benefits and potential issues of the nonavalent HPV vaccine[J].Int J Gynecol Obstet,2017,136(3):1-8
• [15]Joum EA,Giuliano AR,Iversen OE,et a1.A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women[J].N Engl J Med,2015,372(8):711-723
• [16]Centers for Disease Control and Prevention(CDC).National and state vaccination coverage among adolescents aged 13 through 17 years-United States,2010[J].MMWR,2011,60(33):1117-1123
• [17]Dobson SR,Mc Neil S,Dionne M,et al.Immunogenicity of2 doses of HPV vaccine in younger adolescents vs 3 doses in young women:a randomized clinical trial[J].JAMA,2013,309(17):1793-1802
• [18]Garland SM.The Australian experience with the human papillomavirus vaccine[J].Clin Ther,2014,36(1):17-23
• [19]Bansal A,Singh MP,Rai B.Human papillomavirus-associated cancers:a growing global problem[J].Int J Appl Basic Med Res,2016,6(2):84-89
• [20]Bhatia R,Kavanagh K,Cubie HA,et al.Use of HPV testing for cervical screening in vaccinated women-insights from the SHEVa(Scottish HPV Prevalence in Vaccinated Women)study[J].Int J Cancer,2016,138(12):2922-2931
• [21]Tota JE,Ramanakumar AV,Jiang M,et al.Epidemiologic approaches to evaluating the potential for human papillomavirus type replacement postvaccination[J].Am J Epidemiol,2013,178(4):625-634
• [22]Franco EL,Cuzick J,Hildesheim A,et al.Chapter 20:Issues in planning cervical cancer screening in the era of HPV vaccination[J].Vaccine,2006,24(S3):171-177
• [23]Gertig DM,Brotherton JM,Budd AC,et al.Impact of a population-based HPV vaccination program on cervical abnormalities:a data linkage study[J].BMC Med,2013,11:227
• [24]Palmer TJ,Mc Fadden M,Pollock KGJ,et al.HPV immunization and cervical screening-confirmation of changed performance of cytology as a screening test in immunized women:a retrospective population-based cohort study[J].Br J Cancer,2016,114(5):582-589
• [25]El-Zein M,Richardson L,Franco EL.Cervical cancer screening of HPV vaccinated populations:cytology,molecular testing,both or none[J].J Clin Virol,2016,(76):S62-S68
• [26]Kim JJ,Burger EA,Sy S,et al.Optimal cervical cancer screening in women vaccinated against human papillomavirus[J].J Natl Cancer Inst,2017,109(2):1-9
• [27]Rossi PG,Carozzi F,Federici A,et al.Cervical cancer screening in women vaccinated against human papillomavirus infection:recommendations from a consensus conference[J].Prev Med,2017,98(S1):21-30
• [28]曾选.江西117799例女性HPV基因分型结果回顾性分析[J].江西医药,2017,52(5):459-461
• [29]Calleja-Macias IE,Villa LL,Prado JC,et al.Worldwide genomic diversity of the high-risk human papillomavims types 31,35,52,and 58,four close relatives of human papillomavirus type 16[J].J Virol,2005,79(21):13630-13640
• [30]Wang R,Guo XL,Wisman GB,et al.Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China[J].BMC Infect Dis,2015,4(15):257-267
• [31]Winer RL,Lee SK,Hughes JP,et al.Genital human papillomavirus infection:incidence and risk factors in a cohort of female university students[J].Am J Epidemiol,2003,157(3):218-226
• [32]Yang A,Farmer E,Wu TC,et al.Perspectives for herapeutic HPV vaccine development[J].J Biomed Sci,2016,23(1):75